Previous Close | 0.1500 |
Open | 0.1500 |
Bid | 0.1230 x 0 |
Ask | 0.1471 x 0 |
Day's Range | 0.1500 - 0.1550 |
52 Week Range | 0.1100 - 0.4300 |
Volume | |
Avg. Volume | 20,010 |
Market Cap | 14.673M |
Beta (5Y Monthly) | 1.28 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0400 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics specializing in botanical psilocybin and MDMA, today announced that Mr. William (Bill) Ciprick will be stepping down as Chief Executive Officer due to personal reasons."During his three years of leadership, Bill has played a key role in bringing Optimi's GMP psychedelics to ma
Trial to study Major Depressive Disorder using Optimi's GMP natural psilocybin capsules in conjunction with therapy Vancouver, British Columbia--(Newsfile Corp. - August 28, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics pharmaceuticals specializing in botanical psilocybin and MDMA, is pleased to announce the receipt of a No Objection Letter (NOL) from Health Canada. This authoriz
Vancouver, British Columbia--(Newsfile Corp. - August 16, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada-licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, is pleased to announce it has completed the inaugural export of it's GMP-validated MDMA capsules to Australia for the treatment of PTSD, along with a series of notable corporate developments.MDMA Capsule Export to Austra